B O O K - American College of Rheumatology

tuesday
These collated data will provide the most comprehensive map
of the presence and relative importance of MSK disease ever
developed. There is a great need to allow international groups
access to the findings and support individuals and organizations
to use these data to guide local and global policymakers. This
study group will provide an update of the GBD Study progress
through presentations on systematic reviews of the global
prevalence of, and DALYs associated MSK conditions. Global
strategies for bridging gaps in the availability of MSK populationbased
data and the inequity of access to evidence-based MSK
health care and education will be discussed.
Upon completion of this session, participants should be able to:
• identify the key data required for the calculation of DALYs for
MSK conditions
• identify the regions of the world where population-based MSK
data are deficient
• explain the importance of collecting standardized MSK data
from population-based health surveys
• explain the principles involved in measuring equity and access
to minimum standards of care for MSK conditions
A315
Joint Hypermobility Syndrome
Moderators: Jaime F. Bravo, MD; Nuestra Sra de Los Angeles;
Santiago, Chile
Rodney Grahame, MD; University College Hospital; London,
United Kingdom
6:45 PM
Are Some Joint Hypermobility Criteria More Closely Associated
with Anxiety than Others?
Antonio Bulbena, MD; Hospital del Mar and University; Bilbao,
Spain
7:00 PM
Why is Joint Hypermobility Syndrome so Frequently Missed?
Rodney Grahame, MD; University College Hospital; London,
United Kingdom
7:15 PM
Treatment of Dysautonomia (Chronic Fatigue, Dizziness and
Syncope)
Jaime F. Bravo, MD; Nuestra Sra de Los Angeles; Santiago, Chile
7:45 PM
An Integrated Approach to the Physiotherapy Assessment and
Management of Joint Hypermobility Syndrome
Jane Simmonds, MCSP, MMACP; University of Herfordshire;
Hatfield, Herfordshire, United Kingdom
Session Overview:
The interest about Joint Hypermobility Syndrome among
rheumatologists has increased, but still in most cases the
diagnosis of these patients is not made. There is a need not only
to increase awareness about the condition, but also to learn
how to treat these patients.
Upon completion of this session, participants should be able to:
• appreciate that anxiety is very frequently associated to JHS
and explains many symptoms
• explain that JHS is frequent also in children and that the
diagnosis is seldom made
• treat effectively patients with Dysautonomia, improving
significantly the quality of life of these patients
• appreciate the role of physiotherapy and other allied health
professionals in the management of hypermobility syndrome
B310
Kawasaki Disease in the 21st Century - Genes,
Pathogenesis, and Biologics
Moderators: Anne M. Stevens, MD, PhD; Pediatrics, University of
Washington; Seattle, WA
Polly J. Ferguson, MD; University of Iowa Carver College of
Medicine; Iowa City, IA
6:45 PM
The Pathogenesis of Kawasaki Disease: Novel Insights from
Genetics and Immunology
Rae S.M. Yeung, MD, PhD; Hospital for Sick Children; Toronto,
ON, Canada
7:15 PM
Novel Strategies for Treatment and Monitoring for Kawasaki
Disease
Robert P. Sundel, MD; Children’s Hospital Medical Center;
Boston, MA
7:35 PM
ACR Pediatrics Section Business Meeting
Marisa S. Klein-Gitelman, MD, MPH; Children’s Memorial
Hospital/North Western University; Chicago, IL
Session Overview:
Kawasaki disease is one of the most common forms of vasculitis
affecting children, with coronary artery sequelae leading into
adult years. Over the past decade progress has been made
in identifying patients with atypical Kawasaki disease and
in managing patients resistant to standard therapy. Biologic
immunosuppressive and anticoagulation treatments provide
novel options for treatment. Further, genetic and immunologic
studies provide new insights into the pathogenesis of Kawasaki
disease. A better understanding of the evidence for treatment
and the recent basic science advances will aid adult and
pediatric rheumatologists in the care of patients with Kawasaki
Disease.
Upon completion of this session, participants should be able to:
• recognize the signs and symptoms of typical and atypical KD
and the risk factors for coronary aneurysms in children with
fevers
• describe the genes associated with Kawasaki disease risk, and
hypotheses for pathogenesis
• identify the indications for and recommendations for secondline
immunosuppressive therapy for Kawasaki Disease
patients who do not respond to IVIG, including corticosteroids,
cyclophosphamide, and anti-TNF agents
• know the evidence for recommendations for acute and
chronic anticoagulation for KD
A311
Macrophage Activation Syndrome
Moderators: Randy Q. Cron, MD, PhD; Children’s Hospital of
Alabama; Birmingham, AL
Edward M. Behrens, MD; Children’s Hospital of Philadelphia;
Philadelphia, PA
90
2010 Program Book